Steroids in malignant cord compression

01Core principlesThe concepts and mechanisms needed to understand the subject.

Malignant epidural disease compresses the cord or cauda equina mechanically and produces vasogenic oedema, venous congestion and ischaemia. Dexamethasone reduces oedema and can relieve pain or transiently improve function, but the tumour, bone fragment and instability remain. Neurological state before definitive treatment strongly influences recovery.

NICE NG234 supplies a deliberately moderate 16 mg regimen because available steroid evidence is limited and higher loading schedules carry serious infection, gastrointestinal, metabolic and psychiatric toxicity. The recommendation is not a licence to prescribe in every cancer patient with back pain. Severe pain without neurological signs and haematological malignancy have specific consideration clauses.

Key points

This dexamethasone regimen belongs to metastatic spinal cord compression and direct malignant spinal infiltration; it is not a generic treatment for disc, trauma, epidural abscess or haematoma.
For neurological symptoms or signs of MSCC, NICE says offer 16 mg oral dexamethasone or equivalent parenteral dose as soon as possible, then continue 16 mg daily while awaiting surgery or radiotherapy.
The worked case keeps the medication, urgent whole-spine MRI and definitive-treatment sequence visible in Rapid; steroids are a bridge, not decompression.
If imaging rules out spinal metastases and MSCC after short empirical exposure, discontinue dexamethasone; do not continue because pain improved.
After surgery or when radiotherapy starts, reduce gradually until stopped. If no effective treatment option exists, taper while watching symptoms and withdrawal rather than maintaining automatically.
Monitor blood glucose and offer proton-pump-inhibitor acid suppression during corticosteroid treatment; review infection, mental state, gastrointestinal and muscle toxicity.
Seek haematology advice before steroids for radiologically suspected lymphoma or myeloma without neurological signs; confirmed haematological malignancy has a specialist-directed pathway.

02Mechanisms and patternsImportant relationships and how to distinguish them.

Neurological MSCCRed flag

Cancer plus new limb weakness, gait disturbance, sensory loss, radicular pain or bladder and bowel dysfunction warrants emergency treatment and imaging.

Spinal instabilityRed flag

Mechanical pain on movement, progressive deformity, collapse or severe load-related pain may make mobilisation hazardous and requires stability assessment.

Pain-only disease

Severe spinal pain without neurological signs may justify considering dexamethasone, but this is not the same mandatory neurological regimen.

Haematological possibility

Myeloma and lymphoma can respond rapidly to steroids, potentially altering diagnostic tissue and imaging when neurological compromise is absent.

Steroid toxicity

New thirst, polyuria, infection, dyspepsia, bleeding, agitation, psychosis, weakness or fluid change may reflect treatment harm rather than tumour progression.

Red flags requiring action

Neurological symptoms or signs with suspected MSCC trigger immediate dexamethasone and MRI; pain improvement after a dose does not remove compression.
Rapidly progressive weakness, loss of walking, sphincter dysfunction or an unstable painful spine requires immediate coordinator and spinal-team escalation.
Radiologically suspected lymphoma or myeloma without neurological symptoms needs specialist haematology advice before steroids because tissue diagnosis and tumour appearance may be affected.
Hyperglycaemia, infection, delirium, gastrointestinal bleeding, proximal weakness or psychiatric change can emerge during corticosteroid therapy and require active surveillance.

03Interpreting evidenceInformation, measurements and their limitations.

Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

01
Whole-spine MRI within 24 hours
Why
Confirm MSCC, identify additional levels, define cord or cauda compression and guide surgery or radiotherapy.
Interpretation and limitations
Obtain as soon as possible in neurological MSCC. A positive scan defines anatomy; a negative scan should prompt stopping short empirical dexamethasone and evaluating alternatives.
02
Timed neurological examination
Why
Record power, sensation, reflexes, gait and sphincter function before steroid and definitive intervention.
Interpretation and limitations
Rate of progression influences surgical urgency; transient improvement does not justify delaying decompression or radiotherapy.
03
Blood glucose monitoring
Why
Detect steroid-induced hyperglycaemia from the beginning of treatment and throughout ongoing exposure.
Interpretation and limitations
Rising glucose requires an active diabetes plan and does not automatically require abandoning sight- or cord-preserving treatment.
04
Baseline infection and metabolic assessment
Why
Identify infection, renal and hepatic impairment, electrolyte disturbance and other factors increasing steroid or treatment risk.
Interpretation and limitations
Abnormal results guide monitoring and supportive care while urgent MSCC treatment continues unless a specific contraindication changes it.
05
Biopsy planning when primary is unknown
Why
Obtain diagnostic tissue when cancer identity changes treatment and immediate decompression is not required.
Interpretation and limitations
Suspected lymphoma or myeloma without neurological signs should reach haematology before steroids because pre-biopsy treatment may complicate confirmation.

04Applied reasoningWorked examples connecting principles to decisions.

01Worked caseCancer with new leg weaknessAn adult with known cancer develops a sensory level and progressive bilateral weakness over hours.

1Context: contact the MSCC coordinator, establish time of neurological change, examine power, sensation, gait and sphincters, assess stability and protect movement if instability is suspected.
2Reasoning: recognise neurological MSCC and offer dexamethasone 16 mg orally or equivalent parenteral dose immediately; arrange whole-spine MRI as soon as possible and within 24 hours.
3Outcome: continue 16 mg daily while awaiting urgent surgery or radiotherapy, monitor glucose, give PPI acid suppression and do not allow symptomatic response to delay definitive therapy.
4Verification: after surgery or when radiotherapy begins, reduce dexamethasone gradually; track neurological function, pain, glucose, infection, gastrointestinal harm and withdrawal during the taper.

02Stop or taperImaging exclusion and definitive treatmentMRI excludes MSCC, or surgery or radiotherapy has begun after a period of dexamethasone therapy.

1If spinal metastases and MSCC are ruled out after a short empirical course, discontinue dexamethasone because the treatment indication is absent.
2After surgery or at the start of radiotherapy, reduce gradually until stopped, individualising pace to duration, dose, comorbidity and current symptoms.
3If neurological symptoms recur during reduction, discuss urgently with the MSCC service; if exposure was prolonged, incorporate current adrenal-withdrawal guidance rather than stopping abruptly.

03Haematology boundaryPossible lymphoma or myelomaImaging suggests lymphoma or myeloma with spinal metastases but there are no neurological symptoms or signs.

1Seek specialist haematological advice before starting corticosteroids because rapid tumour response can affect imaging and biopsy yield.
2When haematological malignancy is confirmed, NICE recommends 16 mg promptly and further corticosteroid treatment in discussion with the haematology multidisciplinary team.
3If neurological MSCC is present, preserve emergency cord function while coordinating steroids, diagnostic tissue and definitive therapy with haematology and spine teams.

05Relevant medicines and safetySpecific regimens and precautions where medicines are relevant.

Reduces tumour-associated oedema around metastatic spinal cord compression as a time-limited bridge to definitive surgery or radiotherapy.

Dexamethasone for neurological MSCC

Offer 16 mg orally, or an equivalent parenteral dose, as soon as possible; after the initial dose continue 16 mg orally or equivalent parenterally once daily while awaiting surgery or radiotherapy.

Monitor blood glucose and infection, offer proton-pump-inhibitor acid suppression, and review psychiatric, gastrointestinal and proximal-muscle effects. Do not import this dose into non-malignant compression.

Reduces corticosteroid-associated upper gastrointestinal risk during the acute MSCC treatment course.

Proton-pump inhibitor acid suppression

Offer an age-appropriate formulary PPI at the standard gastroprotection dose while corticosteroid treatment continues; select agent and route from interactions, swallowing and local formulary.

Review renal, electrolyte, infection and interaction risks and stop when gastroprotection is no longer indicated; a PPI does not make extreme steroid doses safe.

06Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.

Record dexamethasone indication, first dose time, route, total daily dose and planned definitive treatment so an empirical course does not continue unnoticed.
Measure blood glucose from initiation and during therapy, with increased frequency in diabetes, sepsis, high readings or prolonged treatment.
Monitor temperature, infection features, mental state, sleep, gastrointestinal symptoms, bleeding, fluid state and proximal strength as exposure accumulates.
Repeat neurological examination and mobility status; steroid response can be temporary and does not show that compression or instability is controlled.
At every transition, document whether dexamethasone is being continued, stopped after exclusion or tapered after definitive treatment, including adrenal-risk and recurrence instructions.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

The dose is daily

The NICE regimen is 16 mg total daily after the initial 16 mg dose, not 16 mg every six hours or an extreme loading schedule.

MRI still leads

Dexamethasone may improve pain or power temporarily, but urgent whole-spine imaging and definitive treatment remain necessary.

Haematology needs nuance

The concern is greatest before confirmation in radiologically suspected lymphoma or myeloma without neurological signs, when expert sequencing protects diagnosis.

Exclusion changes action

If the suspected malignant compression is ruled out after brief exposure, continuing corticosteroid offers toxicity without the target pathology.

Withdrawal depends on exposure

Short empirical treatment after a negative scan can stop, whereas longer courses and post-treatment reduction require gradual individualised withdrawal.

08Common pitfallsFrequent interpretation and management errors.

01
Prescribing 16 mg every six hours instead of the NICE total daily dose.
02
Waiting for MRI confirmation before starting dexamethasone in a patient with neurological signs of suspected MSCC.
03
Continuing empirical steroids after MSCC is excluded or failing to create a taper after definitive treatment.
04
Giving pre-biopsy steroids for suspected lymphoma or myeloma without neurological signs before seeking haematology advice.
05
Omitting glucose surveillance and PPI acid suppression or allowing symptom improvement to delay surgery or radiotherapy.

Find your next topic